We anticipate that the broader therapeutic window in human SMA patients would provide ample opportunity for AAV9-ABE-mediated restoration of SMN protein levels to take place without the need for co-administration of a transient therapeutic. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.